Join to View Full Profile
5841 S Maryland Ave# MC2115Chicago, IL 60637
Phone+1 773-702-5550
Fax+1 773-702-3163
Dr. Kline is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Justin Kline is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice 16 years. He specializes in hematologic oncology and is experienced in hematologic oncology and stem cell transplantation.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007- University of ChicagoResidency, Internal Medicine, 2001 - 2004
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2001
Certifications & Licensure
IL State Medical License 2007 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Stem Cell Transplantation for Patients With Multiple Myeloma Start of enrollment: 2011 Jul 12
- Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Start of enrollment: 2019 Sep 04
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Start of enrollment: 2019 Aug 29
Publications & Presentations
PubMed
- Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes.Nada S Aboelella, Ryan Park, Erting Tang, Nicholas Asby, Joshua D Ho
Signal Transduction and Targeted Therapy. 2026-04-27 - 1 citationsTargeting BCMA in Plasmablastic Lymphoma With Teclistamab: A Case Study of Three Patients.Joseph M Cannova, Adam S DuVall, Justin Kline, Nicholas Feinberg, Geoffrey D Wool
Journal of the National Comprehensive Cancer Network. 2026-02-19 - Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.Reid W Merryman, Justin Kline, Robert A Redd, Harrison Olszewski, Emma Welsh
Blood Neoplasia. 2026-02-01
Journal Articles
- CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell FatesJustin Kline, MD, The Journal of Immunology
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaMark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Abstracts/Posters
- Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCLJustin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune LandscapesJustin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSJustin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Emerging Role of Immune Checkpoint Blockade in the Treatment of Refractory/Relapsed Hodgkin and Non-Hodgkin Lymphoma60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
UChicago Cancer Researchers Share Advances at 2026 AACR Annual MeetingMay 13th, 2026- ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
- New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-cell Lymphoma of the BrainSeptember 28th, 2020
Grant Support
- Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphomaUNIVERSITY OF CHICAGO2023–2028
- Development of antigen multimers for CAR T cell detection and functional profilingUNIVERSITY OF CHICAGO2023–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
